PortalPublikationenCancer-specific mortality free survival rates in non-metasta...

Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence

Standard

Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. / Piccinelli, Mattia L; Panunzio, Andrea; Tappero, Stefano; Cano Garcia, Cristina; Barletta, Francesco; Incesu, Reha-Baris; Tian, Zhe; Luzzago, Stefano; Mistretta, Francesco A; Ferro, Matteo; Saad, Fred; Shariat, Shahrokh F; Tilki, Derya; Briganti, Alberto; Chun, Felix K; Terrone, Carlo; Antonelli, Alessandro; DE Cobelli, Ottavio; Musi, Gennaro; Karakiewicz, Pierre I.

in: MINERVA UROL NEPHROL, Jahrgang 75, Nr. 3, 06.2023, S. 319-328.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Piccinelli, ML, Panunzio, A, Tappero, S, Cano Garcia, C, Barletta, F, Incesu, R-B, Tian, Z, Luzzago, S, Mistretta, FA, Ferro, M, Saad, F, Shariat, SF, Tilki, D, Briganti, A, Chun, FK, Terrone, C, Antonelli, A, DE Cobelli, O, Musi, G & Karakiewicz, PI 2023, 'Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence', MINERVA UROL NEPHROL, Jg. 75, Nr. 3, S. 319-328. https://doi.org/10.23736/S2724-6051.23.05151-0

APA

Piccinelli, M. L., Panunzio, A., Tappero, S., Cano Garcia, C., Barletta, F., Incesu, R-B., Tian, Z., Luzzago, S., Mistretta, F. A., Ferro, M., Saad, F., Shariat, S. F., Tilki, D., Briganti, A., Chun, F. K., Terrone, C., Antonelli, A., DE Cobelli, O., Musi, G., & Karakiewicz, P. I. (2023). Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. MINERVA UROL NEPHROL, 75(3), 319-328. https://doi.org/10.23736/S2724-6051.23.05151-0

Vancouver

Piccinelli ML, Panunzio A, Tappero S, Cano Garcia C, Barletta F, Incesu R-B et al. Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. MINERVA UROL NEPHROL. 2023 Jun;75(3):319-328. https://doi.org/10.23736/S2724-6051.23.05151-0

Bibtex

@article{fcd66d68109f41d284ab11c5301cee55,
title = "Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence",
abstract = "BACKGROUND: To date, five trials testing the effect of adjuvant systemic therapy in surgically treated non-metastatic renal cell carcinoma included patients with non-clear cell histology. We tested the effect of papillary vs. chromophobe histological subtype, stage, and grade on 10-year cancer-specific survival, in patients eligible for ≥1 such trial.METHODS: We identified patients meeting ASSURE, SORCE, EVEREST, PROSPER, or RAMPART trial inclusion criteria in the SEER (2000-2018) database. Kaplan-Meier analyses estimated 10-year survival rates and multivariable Cox regression models tested for the independent predictor status of histological subtype, stage, and grade.RESULTS: We identified 5465 (68%) papillary and 2562 (32%) chromophobe renal cell carcinoma patients. Cancer-specific survival rates at 10 years were 77% in papillary vs. 90% in chromophobe. In multivariable Cox regression models applied to papillary patients, cancer-specific mortality independent predictor status was reached for T3G3-4 (HR 2.9), T4Gany (HR 3.4), TanyN1G1-2 (HR 3.1), and TanyN1G3-4 (HR 8.0, P<0.001), relative to T1/2Gany. In multivariable Cox regression models applied to chromophobe patients, mortality independent predictor status was reached for T3G3-4 (HR 3.6), T4Gany (HR 14.0), TanyN1G1-2 (HR 5.7), and TanyN1G3-4 (HR 15.0, P<0.001), relative to T1/2Gany.CONCLUSIONS: In surgically treated non-metastatic intermediate/high-risk renal cell carcinoma patients, papillary histologic subtype exhibited worse cancer-specific survival than chromophobe histologic subtype. Although stage and grade represented independent predictors in both histological subtype groups, the magnitude of their effect was invariably worse in chromophobe than in papillary patients. In consequence, papillary and chromophobe patients should be considered separate entities instead of being combined under the non-clear cell designation.",
keywords = "Humans, Survival Rate, Carcinoma, Renal Cell, Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Kidney Neoplasms",
author = "Piccinelli, {Mattia L} and Andrea Panunzio and Stefano Tappero and {Cano Garcia}, Cristina and Francesco Barletta and Reha-Baris Incesu and Zhe Tian and Stefano Luzzago and Mistretta, {Francesco A} and Matteo Ferro and Fred Saad and Shariat, {Shahrokh F} and Derya Tilki and Alberto Briganti and Chun, {Felix K} and Carlo Terrone and Alessandro Antonelli and {DE Cobelli}, Ottavio and Gennaro Musi and Karakiewicz, {Pierre I}",
year = "2023",
month = jun,
doi = "10.23736/S2724-6051.23.05151-0",
language = "English",
volume = "75",
pages = "319--328",
journal = "MINERVA UROL NEPHROL",
issn = "2724-6051",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

RIS

TY - JOUR

T1 - Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence

AU - Piccinelli, Mattia L

AU - Panunzio, Andrea

AU - Tappero, Stefano

AU - Cano Garcia, Cristina

AU - Barletta, Francesco

AU - Incesu, Reha-Baris

AU - Tian, Zhe

AU - Luzzago, Stefano

AU - Mistretta, Francesco A

AU - Ferro, Matteo

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Tilki, Derya

AU - Briganti, Alberto

AU - Chun, Felix K

AU - Terrone, Carlo

AU - Antonelli, Alessandro

AU - DE Cobelli, Ottavio

AU - Musi, Gennaro

AU - Karakiewicz, Pierre I

PY - 2023/6

Y1 - 2023/6

N2 - BACKGROUND: To date, five trials testing the effect of adjuvant systemic therapy in surgically treated non-metastatic renal cell carcinoma included patients with non-clear cell histology. We tested the effect of papillary vs. chromophobe histological subtype, stage, and grade on 10-year cancer-specific survival, in patients eligible for ≥1 such trial.METHODS: We identified patients meeting ASSURE, SORCE, EVEREST, PROSPER, or RAMPART trial inclusion criteria in the SEER (2000-2018) database. Kaplan-Meier analyses estimated 10-year survival rates and multivariable Cox regression models tested for the independent predictor status of histological subtype, stage, and grade.RESULTS: We identified 5465 (68%) papillary and 2562 (32%) chromophobe renal cell carcinoma patients. Cancer-specific survival rates at 10 years were 77% in papillary vs. 90% in chromophobe. In multivariable Cox regression models applied to papillary patients, cancer-specific mortality independent predictor status was reached for T3G3-4 (HR 2.9), T4Gany (HR 3.4), TanyN1G1-2 (HR 3.1), and TanyN1G3-4 (HR 8.0, P<0.001), relative to T1/2Gany. In multivariable Cox regression models applied to chromophobe patients, mortality independent predictor status was reached for T3G3-4 (HR 3.6), T4Gany (HR 14.0), TanyN1G1-2 (HR 5.7), and TanyN1G3-4 (HR 15.0, P<0.001), relative to T1/2Gany.CONCLUSIONS: In surgically treated non-metastatic intermediate/high-risk renal cell carcinoma patients, papillary histologic subtype exhibited worse cancer-specific survival than chromophobe histologic subtype. Although stage and grade represented independent predictors in both histological subtype groups, the magnitude of their effect was invariably worse in chromophobe than in papillary patients. In consequence, papillary and chromophobe patients should be considered separate entities instead of being combined under the non-clear cell designation.

AB - BACKGROUND: To date, five trials testing the effect of adjuvant systemic therapy in surgically treated non-metastatic renal cell carcinoma included patients with non-clear cell histology. We tested the effect of papillary vs. chromophobe histological subtype, stage, and grade on 10-year cancer-specific survival, in patients eligible for ≥1 such trial.METHODS: We identified patients meeting ASSURE, SORCE, EVEREST, PROSPER, or RAMPART trial inclusion criteria in the SEER (2000-2018) database. Kaplan-Meier analyses estimated 10-year survival rates and multivariable Cox regression models tested for the independent predictor status of histological subtype, stage, and grade.RESULTS: We identified 5465 (68%) papillary and 2562 (32%) chromophobe renal cell carcinoma patients. Cancer-specific survival rates at 10 years were 77% in papillary vs. 90% in chromophobe. In multivariable Cox regression models applied to papillary patients, cancer-specific mortality independent predictor status was reached for T3G3-4 (HR 2.9), T4Gany (HR 3.4), TanyN1G1-2 (HR 3.1), and TanyN1G3-4 (HR 8.0, P<0.001), relative to T1/2Gany. In multivariable Cox regression models applied to chromophobe patients, mortality independent predictor status was reached for T3G3-4 (HR 3.6), T4Gany (HR 14.0), TanyN1G1-2 (HR 5.7), and TanyN1G3-4 (HR 15.0, P<0.001), relative to T1/2Gany.CONCLUSIONS: In surgically treated non-metastatic intermediate/high-risk renal cell carcinoma patients, papillary histologic subtype exhibited worse cancer-specific survival than chromophobe histologic subtype. Although stage and grade represented independent predictors in both histological subtype groups, the magnitude of their effect was invariably worse in chromophobe than in papillary patients. In consequence, papillary and chromophobe patients should be considered separate entities instead of being combined under the non-clear cell designation.

KW - Humans

KW - Survival Rate

KW - Carcinoma, Renal Cell

KW - Adjuvants, Immunologic

KW - Adjuvants, Pharmaceutic

KW - Kidney Neoplasms

U2 - 10.23736/S2724-6051.23.05151-0

DO - 10.23736/S2724-6051.23.05151-0

M3 - SCORING: Journal article

C2 - 37221827

VL - 75

SP - 319

EP - 328

JO - MINERVA UROL NEPHROL

JF - MINERVA UROL NEPHROL

SN - 2724-6051

IS - 3

ER -